JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Llau, J. V.
Right arrow Articles by Garciá-Pérez, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Llau, J. V.
Right arrow Articles by Garciá-Pérez, M. L.
Anesth Analg 2000;90:770-771
© 2000 International Anesthesia Research Society


LETTERS TO THE EDITOR

Increased Safety in the Administration of Aprotinin: Need for a Test-Dose

J. V. Llau, MD, and M. L. Garciá-Pérez, MD

Service of Anesthesiology and Post-Surgical Critical Care Unit , Hospital Clínico Universitario de Valencia , 46010-Valencia, Spain

We have read with interest the article published by Lentschener et al. (1), in relation to the use of aprotinin in surgery of the spinal column. It highlights the use of this drug for bloodless practice in orthopedic surgery, as recently proposed by various authors (24). Perhaps, the most important immediate adverse events associated with its administration are allergic phenomena, which have created considerable controversy and have even placed doubts on the suitability of this drug in orthopedic surgery (5).

The reason behind this letter is to stress the need for the administration of an IV dose of 10,000 KIU of aprotinin (test dose) before beginning the administration of the complete dose. The time period proposed between the administration of the test dose and start of the perfusion has been 10 min (6), although in our opinion, it should not be less than 20 min. After this time, if no hypersensitivity reactions have appeared, the administration of the complete aprotinin dose seems safe. This measure is recommended before any administration of aprotinin, whether or not the patient may have been exposed on a previous occasion.

Sometimes, it has been suggested to perform the test dose by subcutaneous administration of 50,000 KIU (5 mL) of aprotinin, but the results in this approach are nonspecific and only of questionable clinical relevancy; so we do not recommend this system.

There is no doubt that aprotinin is a promising drug for orthopedic surgery. Its indication continues to be controversial, but because one of the objectives whenever aprotinin is administered must be the safety of its use, the test dose should be included in the protocol for any administration of the drug.

References

  1. Lentschener C, Cottin P, Bouaziz H, et al. Reduction of blood loss and transfusion requirement by aprotinin in posterior lumbar spine fusion. Anesth Analg 1999;89:590–7.[Abstract/Free Full Text]
  2. Janssens M, Joris J, David JL, et al. High-dose aprotinin reduces blood loss in patients undergoing total hip replacement surgery. Anesthesiology 1994;80:23–9.[Web of Science][Medline]
  3. Capdevila X, Calvet Y, Biboulet P, et al. Aprotinin decreases blood loss and homologous transfusions in patients undergoing major orthopedic surgery. Anesthesiology 1998;88:50–7.[Web of Science][Medline]
  4. Llau JV, Aguilar G, Soliveres J, et al. Aprotinin administration reduces blood loss and transfusion requirements in patients undergoing total hip arthroplasty [abstract]. Br J Anaesth 1998;80 (S1):A271.
  5. Kasper SM, Schmidt J, Rütt J. Is aprotinin worth the risk in total hip replacement [letter]? Anesthesiology 1994;81:517–8.[Medline]
  6. Dietrich W, Spath P, Ebell A, Richter JA. Prevalence of anaphylactic reactions to aprotinin: analysis of two hundred forty-eight reexposures to aprotinin in heart operations. J Thorac Cardiovasc Surg 1997;113:194–201.[Abstract/Free Full Text]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Llau, J. V.
Right arrow Articles by Garciá-Pérez, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Llau, J. V.
Right arrow Articles by Garciá-Pérez, M. L.


Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins and Stanford University Libraries' HighWire Press®. Copyright 2000 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press